Short communicationMeasurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy
References (13)
- et al.
Hepatocellular carcinoma and hepatitis B virus
A prospective study of 22707 men in Taiwan
Lancet
(1981) - et al.
Mutation preventing formation of hepatitis e antigen in patients with chronic HBV infection
Lancet
(1989) - et al.
A “new” antigen in leukemia sera
JAMA
(1965) - et al.
Correlation of the hepatitis B surface antigen and e antigens
N. Engl. J. Med.
(1978) - et al.
Clinical virologic and histologic outcome following seroconversion from HBeAg to antiHBe in chronic hepatitis type B
Hepatology
(1986) - et al.
Diagnostic significance of quantitative hepatitis B surface antigen in acute and chronic hepatitis B infection
Eur. J. Clin. Microbiol.
(1982)
Cited by (52)
The role of quantitative hepatitis B surface antigen revisited
2017, Journal of HepatologyCitation Excerpt :Discrepant findings (i.e., a virologic profile of inactive carrier, but elevated liver stiffness values) should prompt further investigation to rule out either an intermittent viral replication responsible for CHB or a liver disease of other etiology. Several studies have shown that the change of serum HBsAg levels during PegIFN therapy mimics the change of both intrahepatic cccDNA and intrahepatic HBsAg, suggesting that a decline in serum HBsAg levels is associated with the induction of an effective anti-HBV immune response [2,56–58]. Therefore, HBsAg levels are a valuable tool for the monitoring of patients treated with PegIFN.
Focus
2013, Journal of HepatologyHBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
2013, Clinics in Liver DiseaseCitation Excerpt :The HBeAg seroconversion rate was observed in 32% in HBeAg(+) patients29 and an HBV DNA less than 400 IU/mL in 19% in HBeAg(−) patients.30 In the early 1990s, HBsAg quantification was already considered to be a promising, simple, and inexpensive method to monitor viral replication in CHB patients who were receiving IFN treatment.31 More recently, the availability of well-standardized commercial assays has renewed interest in the quantitative serum HBsAg as a biomarker for treatment response in CHB.9,10
Hepatitis B surface antigen quantification: Clinical implications and limits in monitoring patients with chronic hepatitis B
2012, Immuno-Analyse et Biologie SpecialiseeHepatitis B surface antigen quantification: A new virologic fal for monitoring of chronic hepatitis B
2012, Revue Francophone des LaboratoiresCitation Excerpt :L’intérêt de la quantification de l’AgHBs pour le suivi des réponses aux traitements à base d’IFN chez les patients AgHBe positifs a été proposé en 1994, lorsqu’une baisse significative du titre d’AgHBs a été observée chez les patients répondeurs à l’IFN avec séroconversion HBe, mais non chez les patients sans séroconversion [12]. Ainsi la quantification de l’AgHBs a été proposée comme moyen de surveillance [12]. Cependant le manque de standardisation des tests de quantification disponibles a empêché sa large diffusion jusqu’à récemment.